Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Nimish Maheshwari, an independent analyst and co-founder of Beat The Street, is an investing platform garnering more than 1,00,000+ followers across social media. 
His deep insights and forensic analysis have been featured in some of India's most prominent publications, including the Economic Times, The Morning Context, The Ken,  Dalal Street Investment Journal, Moneylife by Sucheta Dalal, and TheCore.in.
He has a keen eye for identifying red flags in Indian listed companies and has identified exclusive red flags earlier in Adani, Vedanta, Nykaa, Gland Pharma, Brightcom Group etc.

Market & Forensics Analyst

The Beat Ideas: Solara Active Pharma Science~ Turnaround & Value Unlocking Via Demerger

The Beat Ideas: Sigachi Industries- High Growth, Revenue Diversification, New Category Launch

The Beat Ideas: Blue Jet Healthcare- Rising CDMO Player

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

Solara Active Pharma Sciences / Equity Bottom-Up

Solara Active Pharma Sciences (SOLARA IN)

<ul>
<li>Q4 FY26 delivered Solara's highest revenue, gross margin and EBITDA in eight quarters, led entirely by base business momentum.</li>
<li>The base business now operates at 54% gross margins and 26% EBITDA, comparing favourably with India's leading API companies, while the ibuprofen drag is heading toward resolution.</li>
<li>Once the ibuprofen overhang clears, the true margin power of the underlying business could surprise on the upside and management is quietly preparing for that moment.</li>
</ul>


Q4 FY26 delivered Solara's highest revenue, gross margin and EBITDA in eight quarters, led entirely by base business momentum.
The base business now operates at 54% gross margins and 26% EBITDA, comparing favourably with India's leading API companies, while the ibuprofen drag is heading toward resolution.
Once the ibuprofen overhang clears, the true margin power of the underlying business could surprise on the upside and management is quietly preparing for that moment.


솔라라 액티브 파마: 과도한 부채에서 운영 재정비까지